Lexaria Bioscience Corp.
Last updated September 27, 2026
Organization details
- Legal name
- Lexaria Bioscience Corp.
- Former names
- Lexaria Corp.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Nevada
- Headquarters city
- Kelowna
- Headquarters country
- Canada
- Fiscal year end
- August
- Ticker symbol
- LEXX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001348362
- EIN
- 20-2000871
Board of directors
-
Albert L. Reese Jr. · DirectorSince 2023
-
Baljinder Bhullar · DirectorSince 2025
-
Catherine C. Turkel · DirectorSince 2023
-
Christopher Bunka · Director · Chief Executive OfficerSince 2023
-
John Martin Docherty · Director · President & CSOSince 2023
-
Nicholas W. Baxter · DirectorSince 2023
-
Richard Christopher · Director · Chief Executive OfficerSince 2025
-
William Edward McKechnie · DirectorSince 2023
Chief executives
Christopher Bunka
· Chief Executive Officer
Dates unknown
Richard Christopher
· Chief Executive Officer
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 17, 2026 | Christopher Bunka Director | Gift | −100,000 | — | — |
| Jul 30, 2025 | Christopher Bunka Director | Open-market purchase | +11,900 | $0.91 | $10,829 |
| Jul 29, 2025 | Christopher Bunka Director | Open-market purchase | +15,600 | $0.92 | $14,352 |
| Jul 29, 2025 | William Edward McKechnie Director | Open-market purchase | +5,000 | $0.91 | $4,550 |
| Jul 29, 2025 | John Martin Docherty Director, Officer (President & CSO) | Open-market purchase | +5,376 | $0.93 | $5,000 |
| Jul 29, 2025 | Carle Vanessa Officer (Secretary) | Open-market purchase | +750 | $0.91 | $683 |
| Jul 29, 2025 | Richard Christopher Director, Officer (Chief Executive Officer) | Open-market purchase | +15,000 | $0.91 | $13,650 |
| Jan 7, 2025 | Christopher Bunka Director | Grant or award | +100,000 | — | — |
| Dec 3, 2024 | CHRISTOPHER RICHARD Officer (Chief Executive Officer) | Open-market purchase | +27,172 | $2.47 | $67,115 |
| Dec 2, 2024 | CHRISTOPHER RICHARD Officer (Chief Executive Officer) | Open-market purchase | +22,828 | $2.24 | $51,135 |
| Aug 12, 2024 | Catherine C. Turkel Director | Open-market purchase | +1,600 | $3.13 | $5,008 |
| Jul 31, 2024 | Carle Vanessa Officer (Secretary) | Open-market sale | −2,567 | $4.00 | $10,268 |
| May 14, 2024 | Carle Vanessa Officer (Secretary) | Option exercise | +2,500 | $1.15 | $2,875 |
| Feb 9, 2023 | Catherine C. Turkel Director | Open-market purchase | +1,500 | $2.84 | $4,260 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.